New Agents for Youth-Onset Type 2 Diabetes Finally in Sight

There are limited treatment options for children and youth with type 2 diabetes, but a few novel therapies beyond metformin are on the horizon, experts told the virtual American Diabetes Association (ADA) 81st Scientific Sessions. “Type 2 diabetes in youth only emerged as a well-recognized pediatric medical problem in the 1990s and the first decade of the 21st century,” session […]

Read more

Assays May Guide SGLT2 Inhibitor Use in High CV-Risk Diabetes

Heart failure (HF) guidelines and practice have been quick to embrace the sodium-glucose cotransporter 2 (SGLT2) inhibitor drug class after DAPA-HF, EMPEROR-Reduced, and other trials suggested that, apparently as a class, they cut cardiovascular (CV) risk in patients with heart failure and reduced ejection fraction (HFrEF) both with and without diabetes. But how they achieve that is poorly understood, and […]

Read more

Women, Black, Asian Patients Least Likely to Get SGLT2 Inhibitors

In a large cohort of insured American patients with type 2 diabetes, those who were Black, Asian, female, or living in a low-income household were less likely to undergo treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor from 2015 (the year that the results of the EMPA-REG trial were published) to 2019. Moreover, these treatment disparities persisted among patients with […]

Read more

‘Painless’ Glucose Monitors: Do They Help Patients With Diabetes?

In the nation’s battle against the diabetes epidemic, the go-to weapon being aggressively promoted to patients is as small as a quarter and worn on the belly or arm. A continuous glucose monitor holds a tiny sensor that’s inserted just under the skin, alleviating the need for patients to prick their fingers every day to check blood sugar. The monitor […]

Read more